
    
      A bioequivalence study of a single dose of the fixed-dose combination of fluticasone
      propionate and salmeterol xinafoate inhalation powder administered from Fluticasone
      propionate 100 mcg and Salmeterol xinafoate 50 mcg inhalation powder/Respirent
      Pharmaceuticals (test-Τ) as 2 inhalations and SERETIDE DISKUS® 100/50 mcg inhalation
      powder/GSK (reference-R) in healthy volunteers under fasting conditions with charcoal
      blockade. The study will be one-center crossover, randomized, 2-period, 2-sequence (RT and
      TR), single dose, laboratory-blinded.
    
  